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ntering  a  new  era  in  the  treatment  of  hepatitis  CTreatment of hepatitis C virus (HCV) infection was formally ini-
iated in the early Eighties with the experimental administration
f interferon to patients with non-A, non-B hepatitis, at a time
hen a serological diagnosis of the infection was still far from being
vailable. Thirty years later, with the regulatory approvals of the
ucleotide polymerase inhibitor sofosbuvir in the U.S. (December 3,
013), Canada (December 12, 2013) and European Union (January
7, 2014), the most awaited, golden era of interferon-free ther-
py for chronic hepatitis C, has begun. Such a remarkable shift in
he therapeutic paradigm of hepatitis C has recently been consol-
dated by the publication on the row of a series of multinational
tudies with all-oral regimens: one combining sofosbuvir with riba-
irin or the inhibitors of the NS5A replication complex daclatasvir
r ledipasvir or the second wave inhibitors of NS3/4A protease,
imeprevir, and another one based on multiple direct acting antivi-
al agents (DAAs) including an inhibitor of NS3/4 protease and the
S5A replication complex and a non nucleoside inhibitor of NS5B
olymerase of HCV. Remarkably, all regimens combining more than
ne DAA led to the permanent virological cure of more than 90%
f the previously difﬁcult-to-cure patients infected by genotype 1
CV following a course of 12 weeks of therapy, only. While the suc-
ess of these regimens was anticipated at the last meeting of the
uropean Association for the Study of the Liver (EASL, London April
014), in the same meeting this was topped by the reports of equally
ffective oral regimens administered for 6–8 weeks only. This
learly indicates that interferon-based therapy of hepatitis C with
ts burden of adverse effects and limited patient access has come to
n end and is ready to be replaced by user friendly regimens that
rant for universal patients access and cure of hepatitis C. This rapid,
nd to some extent, dramatic shift in the therapeutic paradigm of
epatitis C comes at the expense of harsh arguments in the ﬁeld of
istributive justice. The therapeutic revolution of HCV will not be
aking place at the same pace in every country, even in the industri-
lized world, being strongly constrained by the burden of costs that
as solicited treatment strategies driven by cost effectiveness cri-
eria. This was one of the concerns that led EASL to release updated
ecommendations for the treatment of hepatitis C even before
eld practice data with these regimens had become available. Rec-
mmendations still also include interferon-based regimens with
imeprevir or daclatasvir to treat the prevalent population infected
y HCV genotype 1, with the clear objective of counterbalancing the
isproportionate costs of the newer all oral combinations of DAA’s.
ndeed, the economic burden of the new DAAs is not a trivial point,
iven that 150 million people among the 170 million infected with
CV live outside the target high income market, thereby having in
he best case scenario a yet limited access to interferon, only. While
he high cost of DAAs and absence of effective screening programs
ttp://dx.doi.org/10.1016/j.dld.2014.10.001
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Oare  real hurdles against strategies of global eradication of HCV
infection, the breakthrough represented by the arrival of all oral
therapeutic regimens has fueled discussions on which strategies
should be undertaken to comply with the expectations of patients
and their advocacies. Given the current prices of oral regimens,
treating all comers with the aim of eradicating HCV stands as the
least affordable strategy, even though this approach would have the
beneﬁt of a reduction of liver related mortality in the general popu-
lation. Under the perspective of a life-saving strategy, an alternative
choice would simply be to treat selected groups of patients, such as
those with severe hepatitis and those who are unﬁt or contraindi-
cated to receive interferon, an approach considered by many far
from being cost effective, yet respectful of widely accepted criteria
of prioritization. In the present issue of DLD, the new therapeutic
regimens of HCV are critically presented and discussed by world-
wide renown opinion leaders, thereby offering the readers a chance
of directly evaluating the pros and cons of the above mentioned
strategies for HCV therapy.
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